Navigation Links
Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
Date:2/3/2011

MALVERN, Pa., Feb. 3, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, will release results for the fourth quarter and full year 2010 on Thursday, February 10, 2011 before the opening of the U.S. financial markets. The Company will also conduct a conference call that day at 10:00 a.m. ET to discuss results and highlights of the fourth quarter and full year 2010.  The presentation slides to be used during the call will be available on the "For Investors" section of the Company's web site under the "Presentations" tab beginning at 7 a.m. ET on Thursday, February 10, 2011.  A web cast of the conference call and the presentation slides will be available on the "For Investors" section of the Company's web site under the "Events" tab beginning at 10:00 a.m. ET on Thursday, February 10, 2011.  A question and answer session will follow the presentation.  

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO)

Mr. Armando Anido, Chief Executive Officer and President, will host the conference call.Conference call details:Date:

Thursday, February 10, 2011Time:

10:00 a.m. ETDial-in (U.S.):

800-798-2864Dial-in (International):

617-614-6206Web cast:

http://www.auxilium.com Passcode:

AUXILIUMTo access an audio replay of the call:Access number (U.S.):

888-286-8010Access number (International):

617-801-6888Replay Passcode #:

49964872About AuxiliumAuxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences, such as urologists, endocrinologists, certain targeted primary care physicians, hand surgeons, subsets of orthopedic, general, and plastic surgeons who focus on the hand, and rheumatologists.  Auxilium markets XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord and Testim® 1%, a testosterone gel, for the topical treatment of hypogonadism.  Auxilium has four projects in clinical development.  XIAFLEX is in phase III of development for the treatment of Peyronie's disease and is in phase II of development for treatment of Frozen Shoulder syndrome (Adhesive Capsulitis).  Auxilium's transmucosal film product candidate for the treatment of overactive bladder (AA4010) and its fentanyl pain product using its transmucosal delivery system are in phase I of development.  The Company is currently seeking a partner to further develop these product candidates.  Auxilium has rights to additional pain products and products for hormone replacement and urologic disease using its transmucosal film delivery system.  Auxilium also has rights to pursue additional indications for XIAFLEX.  For additional information, visit http://www.auxilium.com.

AUXILIUM SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company's intention to announce the fourth quarter and full year 2010 results; and products in development for Peyronie's disease, Frozen Shoulder syndrome, overactive bladder, pain, hormone replacement and urologic disease. All statements other than statements of historical facts contained in this release, including but not limited to, statements regarding future expectations, plans and prospects for the Company, statements regarding forward-looking financial information and other statements containing the words "believe," "appears," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," and similar expressions, as they relate to the Company, constitute forward-looking statements. Actual results may differ materially from those reflected in these forward-looking statements due to various factors, including further evaluation of clinical data, results of clinical trials, the performance of third-party service providers, decisions by regulatory authorities regarding whether or when to proceed to the next phase of clinical trials, general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2009 under the heading "Risk Factors," and in Auxilium's Quarterly Report on Form 10-Q for the period ended September 30, 2010, which are on file with the Securities and Exchange Commission (the "SEC") and may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov or by means of the Company's home page on the Internet at http://www.auxilium.com under the heading "For Investors -- SEC Filings." There may be additional risks that the Company does not presently know or that the Company currently believes are immaterial which could also cause actual results to differ from those contained in forward-looking statements. Given these risks and uncertainties, any or all of the forward-looking statements contained in this release may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide the Company's expectations, plans or forecasts of future events and views as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company's assessments to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's assessments as of any date subsequent to the date of this release.

For More Information, Contact:James E. Fickenscher / CFO

William Q. Sargent, Jr. / V.P., I.R. Auxilium Pharmaceuticals, Inc.

Auxilium Pharmaceuticals, Inc.(484) 321-5900

(484) 321-5900jfickenscher@auxilium.com

wsargent@auxilium.com
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vanda Pharmaceuticals to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
2. Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval
3. Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV™ (acetaminophen) Injection
4. Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
5. Takeda and Zinfandel Pharmaceuticals Sign Licensing Agreement for Alzheimers Disease Biomarker in Combination with Pioglitazone
6. Savient Pharmaceuticals Provides Business Update
7. Anthera Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
8. Anadys Pharmaceuticals Augments Management Team and Board of Directors
9. Isis Pharmaceuticals Adds Two New Drugs to Development Pipeline
10. Onyx Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
11. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... ... The award-winning producers behind the American Farmer series proudly ... at helping farmers solve the problem of nitrogen loss. The upcoming episode is ... RFD-TV. Check your local listings for more info. , As a global ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... Huron Digital Pathology , a provider of whole slide imaging solutions, are ... conference . The workshop, entitled “Successfully Deploying a Best-in-Class Strategy for Digital Pathology,” ...
(Date:9/20/2017)... Aurora, Ohio (PRWEB) , ... September 20, 2017 ... ... automation, systems integration, and building management solutions, announced today the opening of an ... customers in Taiwan and the Greater China region, while developing new relationships in ...
(Date:9/19/2017)... Poway, CA (PRWEB) , ... September 19, 2017 , ... VetStem Biopharma ’s CEO ... H. Riordan PA, PhD in Riordan’s new book "Stem Cell Therapy: A Rising Tide". ... past 14 years. They bonded over an interest in the potential of stem cell ...
Breaking Biology Technology:
(Date:6/14/2017)... June 15, 2017  IBM (NYSE: IBM ) is introducing ... event dedicated to developing collaboration between startups and global businesses, ... 15-17. During the event, nine startups will showcase the solutions ... various industries. France ... market, with a 30 percent increase in the number of ...
(Date:5/16/2017)... 2017   Bridge Patient Portal , an ... MD EMR Systems , an electronic medical record ... have established a partnership to build an interface ... GE Centricity™ products, including Centricity Practice Solution (CPS), ... These new integrations will allow healthcare delivery networks ...
(Date:4/19/2017)... York , April 19, 2017 ... as its vendor landscape is marked by the presence ... market is however held by five major players - ... Together these companies accounted for nearly 61% of the ... the leading companies in the global military biometrics market ...
Breaking Biology News(10 mins):